JP2022518929A5 - - Google Patents

Info

Publication number
JP2022518929A5
JP2022518929A5 JP2021544144A JP2021544144A JP2022518929A5 JP 2022518929 A5 JP2022518929 A5 JP 2022518929A5 JP 2021544144 A JP2021544144 A JP 2021544144A JP 2021544144 A JP2021544144 A JP 2021544144A JP 2022518929 A5 JP2022518929 A5 JP 2022518929A5
Authority
JP
Japan
Prior art keywords
nucleic acid
sequence
modified
acid bases
equal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021544144A
Other languages
English (en)
Japanese (ja)
Other versions
JP7557469B2 (ja
JP2022518929A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015701 external-priority patent/WO2020160163A1/en
Publication of JP2022518929A publication Critical patent/JP2022518929A/ja
Publication of JP2022518929A5 publication Critical patent/JP2022518929A5/ja
Priority to JP2024158813A priority Critical patent/JP2025000693A/ja
Application granted granted Critical
Publication of JP7557469B2 publication Critical patent/JP7557469B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021544144A 2019-01-29 2020-01-29 Ａｐｐの発現を低減するための化合物及び方法 Active JP7557469B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024158813A JP2025000693A (ja) 2019-01-29 2024-09-13 Ａｐｐの発現を低減するための化合物及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962798353P 2019-01-29 2019-01-29
US62/798,353 2019-01-29
US201962841169P 2019-04-30 2019-04-30
US62/841,169 2019-04-30
US201962915764P 2019-10-16 2019-10-16
US62/915,764 2019-10-16
PCT/US2020/015701 WO2020160163A1 (en) 2019-01-29 2020-01-29 Compounds and methods for reducing app expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024158813A Division JP2025000693A (ja) 2019-01-29 2024-09-13 Ａｐｐの発現を低減するための化合物及び方法

Publications (3)

Publication Number Publication Date
JP2022518929A JP2022518929A (ja) 2022-03-17
JP2022518929A5 true JP2022518929A5 (https=) 2023-02-02
JP7557469B2 JP7557469B2 (ja) 2024-09-27

Family

ID=71840111

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544144A Active JP7557469B2 (ja) 2019-01-29 2020-01-29 Ａｐｐの発現を低減するための化合物及び方法
JP2024158813A Pending JP2025000693A (ja) 2019-01-29 2024-09-13 Ａｐｐの発現を低減するための化合物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024158813A Pending JP2025000693A (ja) 2019-01-29 2024-09-13 Ａｐｐの発現を低減するための化合物及び方法

Country Status (6)

Country Link
US (1) US20220380773A1 (https=)
EP (1) EP3918073A4 (https=)
JP (2) JP7557469B2 (https=)
TW (1) TW202043472A (https=)
UY (1) UY38562A (https=)
WO (1) WO2020160163A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006528XA (en) 2018-01-12 2020-08-28 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof
CN120310791A (zh) 2018-01-12 2025-07-15 百时美施贵宝公司 靶向α-突触核蛋白的反义寡核苷酸及其用途
US11732260B2 (en) 2018-03-02 2023-08-22 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-β precursor protein
AU2019405783B2 (en) * 2018-12-19 2026-03-26 Alnylam Pharmaceuticals, Inc. Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof
EP3947680A2 (en) * 2019-04-03 2022-02-09 Bristol-Myers Squibb Company Angptl2 antisense oligonucleotides and uses thereof
KR20220062517A (ko) 2019-08-15 2022-05-17 아이오니스 파마수티컬즈, 인코포레이티드 결합 변형된 올리고머 화합물 및 이의 용도
CA3189922A1 (en) 2020-07-28 2022-02-03 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing app expression
US20240117349A1 (en) * 2021-01-29 2024-04-11 Alnylam Pharmaceuticals, Inc. iRNA COMPOSITIONS AND METHODS FOR SILENCING AMYLOID PRECURSOR PROTEIN (APP)
CN118369427A (zh) * 2021-10-15 2024-07-19 阿尔尼拉姆医药品有限公司 肝外递送irna组合物及其使用方法
WO2025045195A1 (zh) * 2023-08-31 2025-03-06 上海拓界生物医药科技有限公司 靶向APP的RNAi剂及其医药用途
WO2025228429A1 (zh) * 2024-04-30 2025-11-06 北京安龙生物医药有限公司 靶向淀粉样前体蛋白基因的寡核苷酸及其用途
WO2025261396A1 (zh) * 2024-06-18 2025-12-26 艾码生物科技(南京)有限公司 靶向app的rna干扰方法、核酸及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013114A1 (en) * 1991-12-24 1993-07-08 Isis Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR MODULATING β-AMYLOID
US20030232435A1 (en) * 2002-06-14 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of amyloid beta protein precursor expression
GB0324854D0 (en) * 2003-10-24 2003-11-26 Expresson Biosystems Ltd App/ena antisense
WO2009105572A2 (en) 2008-02-19 2009-08-27 Edunn Biotechonology Inc. Antisense modulation of amyloid beta protein expression
US20100190807A1 (en) * 2008-08-26 2010-07-29 Senex Biotechnology, Inc. CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein
WO2011130742A2 (en) * 2010-04-16 2011-10-20 Wisconsin Alumni Research Foundation Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens
JP2016521556A (ja) 2013-06-07 2016-07-25 ラナ セラピューティクス インコーポレイテッド Ｆｏｘｐ３発現を調節するための組成物及び方法
JP2016531570A (ja) 2013-08-16 2016-10-13 ラナ セラピューティクス インコーポレイテッド ユークロマチン領域を標的とするオリゴヌクレオチド
US10221414B2 (en) 2013-10-11 2019-03-05 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
WO2015168172A1 (en) 2014-04-28 2015-11-05 Isis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
US11732260B2 (en) * 2018-03-02 2023-08-22 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-β precursor protein

Similar Documents

Publication Publication Date Title
JP2022518929A5 (https=)
JP7354342B2 (ja) タウ発現を調節するための組成物
JP2021530204A5 (https=)
JP6622214B2 (ja) Ｓｏｄ−１発現を調節するための組成物
JP6126009B2 (ja) α−シヌクレイン発現の調節
JP2022515193A5 (https=)
AU2019384181B2 (en) Compounds and methods for reducing prion expression
JP2022520986A5 (https=)
TW201831686A (zh) α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法
JP2021522800A5 (https=)
JP7446443B2 (ja) Ｓｍｎ２を調節するための化合物及び方法
MX2015003841A (es) Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica.
JP2021502095A5 (https=)
TW202113079A (zh) 經修飾之間隙子寡核苷酸及其使用方法
JP2022518929A (ja) Ａｐｐの発現を低減するための化合物及び方法
JP2022533358A5 (https=)
JP2023536472A (ja) Ａｐｐの発現を低減するための化合物及び方法
JP2023536994A5 (https=)
CN118451183A (zh) 用于调节scn1a表达的化合物和方法
WO2021153747A1 (ja) Ａｔｎ１のアンチセンスオリゴヌクレオチド
JP2022515140A5 (https=)
JP2018525015A (ja) 脊髄性筋萎縮症におけるエクソン包含のための修飾アンチセンスオリゴマー
JP2022500079A5 (https=)
JP2023543215A5 (https=)
JP2023528755A5 (https=)